NCT05465941

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase II Clinical Trial of PLX038 in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Detailed description

PRIMARY OBJECTIVE: I. To estimate the overall tumor response rate (overall response rate \[ORR\], that is, complete response \[CR\] + partial response \[PR\], according to Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\] of PLX038 in the setting of metastatic platinum resistant high grade serous ovarian cancer. SECONDARY OBJECTIVES: I. To estimate the progression-free survival and overall survival of treatment with PLX038. II. To describe and assess tolerability of PLX038. III. Measure PLX038 induced tumor TOP1-deoxyribonucleic acid (DNA) covalent complexes (TOP1cc) in pretreatment and Cycle 1 Day 8 biopsies to confirm persistent stabilization of TOP1cc and evaluate association with tumor response rate. CORRELATIVE RESEARCH: I. Measure TOP1cc in circulating tumor cells and evaluate association with TOP1cc in tumor tissue and tumor response rate. II. Assess homologous repair status and association with tumor response. III. Assess expression of SN-38 transports by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and association with tumor response. IV. Assess pharmacokinetics of SN-38 and SN-38G as well as their association with gastrointestinal (GI) toxicity. V. Assess the gut microbiota and evaluate association with GI toxicity profile. OUTLINE: Patients receive PLX038 intravenously (IV) over 1 hour on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT), biopsy, as well as blood and stool sample collection during screening and on the trial. After completion of study treatment, patients are followed up at 30 days and every 6 months for up to 5 years.

Conditions

• Platinum-Resistant Fallopian Tube Carcinoma
• Platinum-Resistant Ovarian Carcinoma
• Platinum-Resistant Primary Peritoneal Carcinoma
• Stage IV Fallopian Tube Cancer AJCC v8
• Stage IV Ovarian Cancer AJCC v8
• Stage IV Primary Peritoneal Cancer AJCC v8

Interventions

Type	Name	Description
PROCEDURE	Biopsy	Undergo biopsy
DRUG	Pegylated SN-38 Conjugate PLX038	Given IV
PROCEDURE	Computed Tomography	Undergo CT
PROCEDURE	Biospecimen Collection	Undergo blood and stool sample collection

Timeline

• Start date: 2022-09-14
• Primary completion: 2027-02-15
• Completion: 2031-12-31
• First posted: 2022-07-20
• Last updated: 2026-02-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study